Mineralys Therapeutics Common Stock Market Value
| MLYS Stock | 30.89 1.20 3.74% |
| Symbol | Mineralys |
Is there potential for Biotechnology market expansion? Will Mineralys introduce new products? Factors like these will boost the valuation of Mineralys Therapeutics. Expected growth trajectory for Mineralys significantly influences the price investors are willing to assign. Understanding fair value requires weighing current performance against future potential. All the valuation information about Mineralys Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Mineralys Therapeutics is measured differently than its book value, which is the value of Mineralys that is recorded on the company's balance sheet. Investors also form their own opinion of Mineralys Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mineralys Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Mineralys Therapeutics' market value can be influenced by many factors that don't directly affect Mineralys Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Mineralys Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Mineralys Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Mineralys Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Mineralys Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Mineralys Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Mineralys Therapeutics.
| 11/02/2025 |
| 01/31/2026 |
If you would invest 0.00 in Mineralys Therapeutics on November 2, 2025 and sell it all today you would earn a total of 0.00 from holding Mineralys Therapeutics Common or generate 0.0% return on investment in Mineralys Therapeutics over 90 days. Mineralys Therapeutics is related to or competes with Gilead Sciences, Sanofi ADR, Amgen, GlaxoSmithKline PLC, Bristol Myers, Stryker, and Boston Scientific. Mineralys Therapeutics is entity of United States More
Mineralys Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Mineralys Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Mineralys Therapeutics Common upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.09) | |||
| Maximum Drawdown | 24.81 | |||
| Value At Risk | (6.28) | |||
| Potential Upside | 5.87 |
Mineralys Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mineralys Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Mineralys Therapeutics' standard deviation. In reality, there are many statistical measures that can use Mineralys Therapeutics historical prices to predict the future Mineralys Therapeutics' volatility.| Risk Adjusted Performance | (0.04) | |||
| Jensen Alpha | (0.34) | |||
| Total Risk Alpha | (0.54) | |||
| Treynor Ratio | (0.21) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Mineralys Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Mineralys Therapeutics January 31, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.20) | |||
| Mean Deviation | 2.39 | |||
| Coefficient Of Variation | (1,451) | |||
| Standard Deviation | 3.79 | |||
| Variance | 14.35 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.34) | |||
| Total Risk Alpha | (0.54) | |||
| Treynor Ratio | (0.21) | |||
| Maximum Drawdown | 24.81 | |||
| Value At Risk | (6.28) | |||
| Potential Upside | 5.87 | |||
| Skewness | 1.59 | |||
| Kurtosis | 6.46 |
Mineralys Therapeutics Backtested Returns
Mineralys Therapeutics has Sharpe Ratio of -0.0808, which conveys that the firm had a -0.0808 % return per unit of risk over the last 3 months. Mineralys Therapeutics exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Mineralys Therapeutics' Mean Deviation of 2.39, standard deviation of 3.79, and Risk Adjusted Performance of (0.04) to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 1.28, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Mineralys Therapeutics will likely underperform. At this point, Mineralys Therapeutics has a negative expected return of -0.32%. Please make sure to verify Mineralys Therapeutics' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and market facilitation index , to decide if Mineralys Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.42 |
Average predictability
Mineralys Therapeutics Common has average predictability. Overlapping area represents the amount of predictability between Mineralys Therapeutics time series from 2nd of November 2025 to 17th of December 2025 and 17th of December 2025 to 31st of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Mineralys Therapeutics price movement. The serial correlation of 0.42 indicates that just about 42.0% of current Mineralys Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.42 | |
| Spearman Rank Test | 0.38 | |
| Residual Average | 0.0 | |
| Price Variance | 4.52 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics' price analysis, check to measure Mineralys Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics is operating at the current time. Most of Mineralys Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics' price. Additionally, you may evaluate how the addition of Mineralys Therapeutics to your portfolios can decrease your overall portfolio volatility.